This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
Invitrogen
other brands :
NeoMarkers, Lab Vision, Endogen, Pierce, BioSource International, Zymed Laboratories, Caltag, Molecular Probes, Research Genetics, Life Technologies, Applied Biosystems, GIBCO BRL, ABgene, Dynal, Affinity BioReagents, Nunc, Invitrogen, NatuTec, Oxoid, Richard-Allan Scientific, Arcturus, Perseptive Biosystems, Proxeon, eBioscience
product type :
antibody
product name :
Emapalumab Recombinant Monoclonal Antibody
catalog :
MA5-59498
quantity :
1 mg
price :
US 1159.00
clonality :
recombinant
conjugate :
nonconjugated
application :
flow cytometry
product information
Product Type :
Antibody
Product Name :
Emapalumab Recombinant Monoclonal Antibody
Catalog # :
MA5-59498
Quantity :
1 mg
Price :
US 1159.00
Clonality :
Recombinant Monoclonal
Purity :
protein A
Reactivity :
Human
Applications :
ELISA: Assay-dependent, Flow Cytometry: Assay-dependent, Functional Assay: Assay-dependent, Surface plasmon resonance: Assay-dependent
Species :
Human
Isotype :
IgG1
Storage :
-20 C, Avoid Freeze/Thaw Cycles
Description :
Emapalumab, also known as NI-0501, is a fully human monoclonal antibody that targets interferon gamma. Emapalumab development was sponsored by NovImmune SA, further developed by Sobi and FDA approved on November 20, 2018. 1, 5 The approval of emapalumab was followed by the designation of orphan pharmaceutical, priority review and breakthrough therapy. 5 As well, emapalumab was given the status of PRIME by the EMA.
Format :
Lyophilized
Applications w/Dilutions :
ELISA: Assay-dependent, Flow Cytometry: Assay-dependent, Functional Assay: Assay-dependent, Surface plasmon resonance: Assay-dependent
Aliases :
emapalumab-lzsg; NI-0501
company information
Invitrogen
Thermo Fisher Scientific
81 Wyman Street
Waltham, MA USA 02451
https://www.thermofisher.com81 Wyman Street
Waltham, MA USA 02451
800-678-5599
headquarters: USA
questions and comments
